MEP4508A - Nove kompozicije glikolipidnog adjuvansa - Google Patents

Nove kompozicije glikolipidnog adjuvansa

Info

Publication number
MEP4508A
MEP4508A MEP-45/08A MEP4508A MEP4508A ME P4508 A MEP4508 A ME P4508A ME P4508 A MEP4508 A ME P4508A ME P4508 A MEP4508 A ME P4508A
Authority
ME
Montenegro
Prior art keywords
adjuvant compositions
glycolipid adjuvant
novel glycolipid
compositions
novel
Prior art date
Application number
MEP-45/08A
Other languages
Bosnian (bs)
English (en)
Inventor
Paul Joseph Dominowski
Ramasamy Mannar Mannan
Sangita Mediratta
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MEP4508A publication Critical patent/MEP4508A/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/155Paramyxoviridae, e.g. parainfluenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/245Herpetoviridae, e.g. herpes simplex virus
    • A61K39/265Infectious rhinotracheitis virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/12Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02Acyclic radicals, not substituted by cyclic structures
    • C07H15/12Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16051Methods of production or purification of viral material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16711Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18311Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18351Methods of production or purification of viral material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18611Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18634Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18611Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18651Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MEP-45/08A 2006-01-26 2007-01-15 Nove kompozicije glikolipidnog adjuvansa MEP4508A (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76227906P 2006-01-26 2006-01-26
US81498406P 2006-06-20 2006-06-20
PCT/IB2007/000258 WO2007085962A2 (en) 2006-01-26 2007-01-15 Novel glycolipid adjuvant compositions

Publications (1)

Publication Number Publication Date
MEP4508A true MEP4508A (hr) 2010-06-10

Family

ID=38309580

Family Applications (3)

Application Number Title Priority Date Filing Date
MEP-2013-95A ME01545B (me) 2006-01-26 2007-01-15 Preparati s novim glikolipidnim adjuvansom
MEP-2008-45A ME00045B (me) 2006-01-26 2007-01-15 Nove kompozicije glikolipidnog adjuvansa
MEP-45/08A MEP4508A (hr) 2006-01-26 2007-01-15 Nove kompozicije glikolipidnog adjuvansa

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MEP-2013-95A ME01545B (me) 2006-01-26 2007-01-15 Preparati s novim glikolipidnim adjuvansom
MEP-2008-45A ME00045B (me) 2006-01-26 2007-01-15 Nove kompozicije glikolipidnog adjuvansa

Country Status (21)

Country Link
US (1) US8460679B2 (hr)
EP (2) EP2481423A1 (hr)
JP (1) JP5538725B2 (hr)
KR (2) KR101202553B1 (hr)
AR (1) AR059192A1 (hr)
AU (1) AU2007209104B2 (hr)
BR (1) BRPI0706709B8 (hr)
CA (1) CA2634888C (hr)
CY (1) CY1114310T1 (hr)
DK (1) DK1991266T3 (hr)
ES (1) ES2425576T3 (hr)
HK (1) HK1128078A1 (hr)
ME (3) ME01545B (hr)
NO (1) NO341463B1 (hr)
NZ (1) NZ569375A (hr)
PL (1) PL1991266T3 (hr)
PT (1) PT1991266E (hr)
RS (2) RS52930B (hr)
RU (1) RU2392965C2 (hr)
TW (1) TWI372631B (hr)
WO (1) WO2007085962A2 (hr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008000261A2 (en) * 2006-06-28 2008-01-03 Statens Serum Institut Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails
WO2009156960A2 (en) * 2008-06-27 2009-12-30 Pfizer Inc. Novel adjuvant compositions
MX2011003535A (es) 2008-10-03 2011-09-21 Novartis Ag Composiciones de virus de herpes bovino-1, vacunas, y metodos.
WO2014141127A1 (en) * 2013-03-15 2014-09-18 Glaxosmithkline Biologicals S.A. Composition containing buffered aminoalkyl glucosaminide phosphate derivatives and its use for enhancing an immune response
JP6586083B2 (ja) 2013-09-19 2019-10-02 ゾエティス・サービシーズ・エルエルシー 油性アジュバント
BR112016012127A2 (pt) 2013-11-26 2017-09-26 Zoetis Services Llc composições para a indução da resposta imunológica
KR20170097116A (ko) 2015-01-16 2017-08-25 조에티스 서비시즈 엘엘씨 구제역 백신
ES2878475T3 (es) * 2015-07-20 2021-11-18 Zoetis Services Llc Composiciones adyuvantes liposomales
GB201703529D0 (en) 2017-03-06 2017-04-19 Cambridge Entpr Ltd Vaccine composition
CN110713520B (zh) * 2019-11-06 2021-01-01 中国石油天然气股份有限公司 油酰基氨基酸-γ-L-谷氨酰-L-半胱氨酰-甘氨酸多肽及其制备与应用
TW202206098A (zh) 2020-08-11 2022-02-16 美商碩騰服務公司 抗冠狀病毒疫苗
TW202214294A (zh) 2020-09-30 2022-04-16 美商碩騰服務公司 具有hyaC及nanP缺失之新穎多殺性巴斯德氏菌株及疫苗

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4291019A (en) * 1979-07-09 1981-09-22 Iowa State University Research Foundation, Inc. Vaccine for infectious bovine rhinotracheitis
DE3213650A1 (de) 1982-04-14 1983-10-27 Bayer Ag, 5090 Leverkusen N-glycosylierte carbonsaeureamid-derivate, verfahren zu ihrer herstellung sowie ihre verwendung zur beeinflussung der koerpereigenen abwehr
DE3403495A1 (de) 1983-11-23 1985-05-30 Bayer Ag, 5090 Leverkusen Phosphorylierte glycosylamide, -harnstoffe, -carbamate und -thiocarbamate, verfahren zu ihrer herstellung sowie ihre verwendung
DE3346623A1 (de) 1983-12-14 1985-07-04 Bayer Ag, 5090 Leverkusen N-glycosylierte harnstoffe, carbamate und thiocarbamate, verfahren zu ihrer herstellung sowie ihre verwendung
DE3521994A1 (de) 1985-06-20 1987-01-02 Bayer Ag N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
NZ232740A (en) * 1989-04-20 1992-06-25 Riker Laboratories Inc Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
US6764682B1 (en) 1994-06-16 2004-07-20 Aventis Pasteur Limited Adjuvant compositions containing more than one adjuvant
US5718904A (en) 1995-06-02 1998-02-17 American Home Products Corporation Adjuvants for viral vaccines
US6290971B1 (en) 1995-06-15 2001-09-18 Aventis Pasteur Limited Adjuvant compositions comprising a mineral salt and another immunostimulating compound
FI109332B (fi) 1998-12-17 2002-07-15 Orion Yhtymae Oyj Toremifeenin liukoisia koostumuksia
MXPA03002890A (es) * 2000-10-02 2004-12-03 Glaxosmithkline Biolog Sa Preparacion de virus con envolvente dividido.

Also Published As

Publication number Publication date
RS52930B (en) 2014-02-28
KR101202553B1 (ko) 2012-11-20
EP1991266A2 (en) 2008-11-19
US8460679B2 (en) 2013-06-11
RS20080318A (en) 2009-05-06
CA2634888A1 (en) 2007-08-02
WO2007085962A3 (en) 2007-12-27
DK1991266T3 (da) 2013-08-26
BRPI0706709B8 (pt) 2021-05-25
PT1991266E (pt) 2013-08-28
WO2007085962A2 (en) 2007-08-02
AU2007209104B2 (en) 2010-04-08
US20070196384A1 (en) 2007-08-23
ME00045B (me) 2010-10-10
AU2007209104A1 (en) 2007-08-02
RU2008129203A (ru) 2010-03-10
TWI372631B (en) 2012-09-21
JP2009524638A (ja) 2009-07-02
EP2481423A1 (en) 2012-08-01
NO341463B1 (no) 2017-11-20
RU2392965C2 (ru) 2010-06-27
JP5538725B2 (ja) 2014-07-02
TW200738268A (en) 2007-10-16
AR059192A1 (es) 2008-03-12
PL1991266T3 (pl) 2013-11-29
NZ569375A (en) 2010-05-28
ME01545B (me) 2014-04-20
EP1991266B1 (en) 2013-06-26
BRPI0706709A2 (pt) 2011-04-05
CY1114310T1 (el) 2016-08-31
KR20080080223A (ko) 2008-09-02
ES2425576T3 (es) 2013-10-16
KR20110140140A (ko) 2011-12-30
BRPI0706709B1 (pt) 2021-03-23
HK1128078A1 (en) 2009-10-16
CA2634888C (en) 2016-06-21
NO20083405L (no) 2008-10-23

Similar Documents

Publication Publication Date Title
MEP4508A (hr) Nove kompozicije glikolipidnog adjuvansa
MX2008001938A (es) Composiciones que contienen alcoxilatos de alcohol graso.
WO2006127394A3 (en) Structured surfactant compositions
AR061494A1 (es) Composiciones detergentes
BR112015029254A2 (pt) composição detergente de baixo ph compreendendo tensoativos não iônicos
AR077283A1 (es) Composiciones detergentes que contienen aminosilicona y metodos para utilizarlas
ATE402135T1 (de) Veresterte alkylalkoxylate als schaumarme tenside
ECSP099429A (es) Formulaciones agroquímicas líquidas basadas en agua
MX2013010149A (es) Desinfectante de amplio espectro.
WO2010108756A3 (de) Wässrige haar- und hautreinigungszusammensetzungen
ATE546513T1 (de) Saure zusammensetzung auf basis einer tensidmischung
MX2014003278A (es) Composiciones detergentes que comprenden sistemas surfactantes primarios que comprenden surfactantes con base de isoprenoide altamente ramificados y otros surfactantes.
MY176046A (en) Composition and method
BR112012016319A2 (pt) sólido, método para produzir um sólido, e, formulação sólida de detergente ou limpador
AR074271A1 (es) Composicion de champu concentrada
DOP2011000025A (es) Metodos para entregar una frangancia
PL1838826T3 (pl) Zastosowanie czwartorzędowego związku amoniowego jako środka solubilizującego i kompozycja zawierająca ten czwartorzędowy związek amoniowy
AR077524A1 (es) Agentes quelantes y uso de los mismos
PE20131219A1 (es) Metodo para la preparacion de acido montelukast en un medio liquido ionico
UA90569C2 (ru) Композиция гликолипидного адьюванта (варианты) и способ ее получения
BRPI0607269A2 (pt) protetores de cisalhamento para colheita por microfiltragem
MY159304A (en) Detergent composition
RU2009137938A (ru) Порошок титаната калия
TW200627093A (en) Developer composition
BR112012026765A2 (pt) processo para fabricação de uma composição detergente líquida